

SABR

PROSTATE TRIAL

SABR (Stereotactic Ablative Body Radiotherapy) is a promising new high-precision, higher-dose-per-day radiotherapy technique for men with favourable-risk prostate cancer.

MORE EFFECTIVE



Image-guided technique spares healthy tissue surrounding the tumour.



Reduced side effects in sexual functioning: 96% of SABR patients retained normal sexual function compared to baseline.


High rates of remission five years after treatment



MORE EFFICIENT

SABR
SABR
SABR
SABR
SABR

VS



5 SABR sessions

39 with standard radiotherapy

Lower treatment cost per patient



\$6,987 39-session EBRT

\$1,470 5-session SABR

↑ 600%

increase in system capacity means more men treated more quickly

Fewer trips to the hospital means savings on gas, parking, time off work and "wear and tear."



JOIN THE TRIAL

From 2015 to 2020, an international clinical trial will take place in Canada to demonstrate results on a large scale.



200 CANADIAN MEN

with favourable-risk prostate cancer



15 CANCER CENTRES

with highly trained principal investigators



5 YEARS

of patient follow-up

SPONSORED BY



WITH



Thank you to our partners who made the SABR Prostate Trial possible. For more information, please visit prostatecure.ca

